Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13543-13555

  Ammayappan, Arun ^a   Peng, Kah Whye ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ECHISTATIN; GUANINE NUCLEOTIDE BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN ENGINEERING; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84888048291     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02240-13     Document Type: Article

References (51)

1. Alajez NM, Mocanu JD, Shi W, Chia MC, Breitbach CJ, Hui AB, Knowles S, Bell JC, Busson P, Takada K, Lo KW, O'Sullivan B, Gullane P, Liu FF. 2008. Efficacy of systemically administered mutant vesicular stomatitis virus (VSVΔ51) combined with radiation for nasopharyngeal carcinoma. Clin. Cancer Res. 14:4891-4897.
2. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ. 2012. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26:1870-1878.
3. Shinozaki K, Ebert O, Woo SL. 2005. Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. Int. J. Cancer 114:659-664.
4. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825.
5. Au GG, Lindberg AM, Barry RD, Shafren DR. 2005. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int. J. Oncol. 26:1471-1476.
6. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. 2002. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 8:527-531.
7. Russell SJ, Peng KW, Bell JC. 2012. Oncolytic virotherapy. Nat. Biotechnol. 30:658-670.
8. Publicover J, Ramsburg E, Robek M, Rose JK. 2006. Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant:viral pathogenesis is linked to induction of tumor necrosis factor alpha. J. Virol. 80:7028-7036.
9. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
10. Kelly EJ, Nace R, Barber GN, Russell SJ. 2010. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J. Virol. 84:1550-1562.
11. Ammayappan A, Nace R, Peng KW, Russell SJ. 2013. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J. Virol. 87:3217-3228.
12. Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JM, Brunner LJ, Kobinger GP. 2004. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78:912-921.
13. Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ. 2013. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J. Virol. 87:3752-3759.
14. Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG. 2008. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther. 15:604-616.
15. Muik A, Kneiske I, Werbizki M, Wilflingseder D, Giroglou T, Ebert O, Kraft A, Dietrich U, Zimmer G, Momma S, von Laer D. 2011. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J. Virol. 85:5679-5684.
16. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. 2012. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum. Gene Ther. 23:484-491.
17. Dreja H, Piechaczyk M. 2006. The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol. J. 3:69. doi:10.1186/1754-422X-3-69.
18. Guibinga GH, Hall FL, Gordon EM, Ruoslahti E, Friedmann T. 2004. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol. Ther. 9:76-84.
19. Padmashali RM, Andreadis ST. 2011. Engineering fibrinogen-binding VSV-G envelope for spatially-and cell-controlled lentivirus delivery through fibrin hydrogels. Biomaterials 32:3330-3339.
20. Yu JH, Schaffer DV. 2006. Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. J. Virol. 80:3285-3292.
21. Schlehuber LD, Rose JK. 2004. Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J. Virol. 78:5079-5087.
22. Takada Y, Ye X, Simon S. 2007. The integrins. Genome Biol. 8:215. doi:10.1186/gb-2007-8-5-215.
23. Desgrosellier JS, Cheresh DA. 2010. Integrins in cancer:biological implications and therapeutic opportunities. Nat. Rev. Cancer 10:9-22.
24. Humphries JD, Byron A, Humphries MJ. 2006. Integrin ligands at a glance. J. Cell Sci. 119:3901-3903.
25. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. 2001. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40:2373-2378.
26. Danhier F, Le Breton A, Preat V. 2012. RGD-based strategies to target αvβ3 integrin in cancer therapy and diagnosis. Mol. Pharm. 9:2961-2973.
27. Allaume X, El-Andaloussi N, Leuchs B, Bonifati S, Kulkarni A, Marttila T, Kaufmann JK, Nettelbeck DM, Kleinschmidt J, Rommelaere J, Marchini A. 2012. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J. Virol. 86:3452-3465.
28. Kim J, Smith T, Idamakanti N, Mulgrew K, Kaloss M, Kylefjord H, Ryan PC, Kaleko M, Stevenson SC. 2002. Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor:improved potency via trimerization. J. Virol. 76:1892-1903.
29. Arosio D, Manzoni L, Araldi EMV, Scolastico C. 2011. Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjug. Chem. 22:664-672.
30. Kim YH, Jeon J, Hong SH, Rhim WK, Lee YS, Youn H, Chung JK, Lee MC, Lee DS, Kang KW, Nam JM. 2011. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small 7:2052-2060.
31. Kumar CC, Nie HM, Rogers CP, Malkowski M, Maxwell E, Catino JJ, Armstrong L. 1997. Biochemical characterization of the binding of echistatin to integrin αvβ3 receptor. J. Pharmacol. Exp. Ther. 283:843-853.
32. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ. 2005. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha v beta 3 and leads to tumor regression. Cancer Res. 65:5292-5300.
33. Bloor S, Maelfait J, Krumbach R, Beyaert R, Randow F. 2010. Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus. Proc. Natl. Acad. Sci. U.S.A. 107:6970-6975.
34. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L, Kawaoka Y, Rose JK. 1998. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72:4704-4711.
35. Arnberg N, Pring-Akerblom P, Wadell G. 2002. Adenovirus type 37 uses sialic acid as a cellular receptor on Chang C cells. J. Virol. 76:8834-8841.
36. Jonsson N, Gullberg M, Israelsson S, Lindberg AM. 2009. A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR. Virol. J. 6:217. doi:10.1186/1743-422X-6-217.
37. Roche S, Rey FA, Gaudin Y, Bressanelli S. 2007. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315:843-848.
38. Staron M, Yang Y, Liu B, Li J, Shen Y, Zuniga-Pflucker JC, Aguila HL, Goldschneider I, Li Z. 2010. gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis. Blood 115:2380-2390.
39. Weekes MP, Antrobus R, Talbot S, Hor S, Simecek N, Smith DL, Bloor S, Randow F, Lehner PJ. 2012. Proteomic plasma membrane profiling reveals an essential role for gp96 in the cell surface expression of LDLR family members, including the LDL receptor and LRP6. J. Proteome Res. 11:1475-1484.
40. Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. 2013. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl. Acad. Sci. U.S.A. 110:7306-7311.
41. Nguyen AT, Hirama T, Chauhan V, Mackenzie R, Milne R. 2006. Binding characteristics of a panel of monoclonal antibodies against the ligand binding domain of the human LDLr. J. Lipid Res. 47:1399-1405.
42. Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, Bell JC, McCart JA, Mahoney D, Stojdl DF. 2010. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 18:1440-1449.
43. Kelly EJ, Hadac EM, Greiner S, Russell SJ. 2008. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 14:1278-1283.
44. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ. 2005. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23:209-214.
45. Ong HT, Trejo TR, Pham LD, Oberg AL, Russell SJ, Peng KW. 2009. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol. Ther. 17:1012-1021.
46. Murugesan SR, Akiyama M, Einfeld DA, Wickham TJ, King CR. 2007. Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor. Int. J. Oncol. 31:813-822.
47. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A. 2012. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int. J. Cancer 130:1937-1947.
48. Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H, Parameshwar M, Vickers SM, Jaffee EM, Huibregtse K, Curiel DT, Dmitriev I. 2001. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 8:969-976.
49. Shi XQ, Fang GG, Shi WF, Bartlett JS. 2006. Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin-binding ability and introduced novel tropism. Hum. Gene Ther. 17:353-361.
50. Aroul-Selvam R, Hubbard T, Sasidharan R. 2004. Domain insertions in protein structures. J. Mol. Biol. 338:633-641.
51. Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, Parato K, Stanford MM, Lichty BD, Fenster A, Kirn D, Atkins H, Bell JC. 2011. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19:886-894.